Literature DB >> 15026352

Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors.

Barbara W Henderson1, Sandra O Gollnick, John W Snyder, Theresa M Busch, Philaretos C Kousis, Richard T Cheney, Janet Morgan.   

Abstract

The rate of light delivery (fluence rate) plays a critical role in photodynamic therapy (PDT) through its control of tumor oxygenation. This study tests the hypothesis that fluence rate also influences the inflammatory responses associated with PDT. PDT regimens of two different fluences (48 and 128 J/cm(2)) were designed for the Colo 26 murine tumor that either conserved or depleted tissue oxygen during PDT using two fluence rates (14 and 112 mW/cm(2)). Tumor oxygenation, extent and regional distribution of tumor damage, and vascular damage were correlated with induction of inflammation as measured by interleukin 6, macrophage inflammatory protein 1 and 2 expression, presence of inflammatory cells, and treatment outcome. Oxygen-conserving low fluence rate PDT of 14 mW/cm(2) at a fluence of 128 J/cm(2) yielded approximately 70-80% tumor cures, whereas the same fluence at the oxygen-depleting fluence rate of 112 mW/cm(2) yielded approximately 10-15% tumor cures. Low fluence rate induced higher levels of apoptosis than high fluence rate PDT as indicated by caspase-3 activity and terminal deoxynucleotidyl transferase-mediated nick end labeling analysis. The latter revealed PDT-protected tumor regions distant from vessels in the high fluence rate conditions, confirming regional tumor hypoxia shown by 2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl) acetamide staining. High fluence at a low fluence rate led to ablation of CD31-stained endothelium, whereas the same fluence at a high fluence rate maintained vessel endothelium. The highest levels of inflammatory cytokines and chemokines and neutrophilic infiltrates were measured with 48 J/cm(2) delivered at 14 mW/cm(2) ( approximately 10-20% cures). The optimally curative PDT regimen (128 J/cm(2) at 14 mW/cm(2)) produced minimal inflammation. Depletion of neutrophils did not significantly change the high cure rates of that regimen but abolished curability in the maximally inflammatory regimen. The data show that a strong inflammatory response can contribute substantially to local tumor control when the PDT regimen is suboptimal. Local inflammation is not a critical factor for tumor control under optimal PDT treatment conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026352     DOI: 10.1158/0008-5472.can-03-3513

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  75 in total

1.  Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.

Authors:  Theresa M Busch; Hsing-Wen Wang; E Paul Wileyto; Guoqiang Yu; Ralph M Bunte
Journal:  Radiat Res       Date:  2010-09       Impact factor: 2.841

2.  Intraoperative optical assessment of photodynamic therapy response of superficial oral squamous cell carcinoma.

Authors:  Daniel J Rohrbach; Nestor Rigual; Hassan Arshad; Erin C Tracy; Michelle T Cooper; Gal Shafirstein; Gregory Wilding; Mihai Merzianu; Heinz Baumann; Barbara W Henderson; Ulas Sunar
Journal:  J Biomed Opt       Date:  2016-01       Impact factor: 3.170

3.  A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer.

Authors:  Anja Bastian; Jessica E Thorpe; Bryan C Disch; Lora C Bailey-Downs; Aleem Gangjee; Ravi K V Devambatla; Jim Henthorn; Kenneth M Humphries; Shraddha S Vadvalkar; Michael A Ihnat
Journal:  J Pharmacol Exp Ther       Date:  2015-02-26       Impact factor: 4.030

4.  IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation.

Authors:  Craig M Brackett; Jason B Muhitch; Sharon S Evans; Sandra O Gollnick
Journal:  J Immunol       Date:  2013-09-11       Impact factor: 5.422

Review 5.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

Review 6.  Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma.

Authors:  Harry Quon; Craig E Grossman; Jarod C Finlay; Timothy C Zhu; Clarice S Clemmens; Kelly M Malloy; Theresa M Busch
Journal:  Photodiagnosis Photodyn Ther       Date:  2011-06       Impact factor: 3.631

Review 7.  The role of photodynamic therapy (PDT) physics.

Authors:  Timothy C Zhu; Jarod C Finlay
Journal:  Med Phys       Date:  2008-07       Impact factor: 4.071

8.  Light delivery over extended time periods enhances the effectiveness of photodynamic therapy.

Authors:  Mukund Seshadri; David A Bellnier; Lurine A Vaughan; Joseph A Spernyak; Richard Mazurchuk; Thomas H Foster; Barbara W Henderson
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

9.  Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.

Authors:  Theresa M Busch; Xiaoman Xing; Guoqiang Yu; Arjun Yodh; E Paul Wileyto; Hsing-Wen Wang; Turgut Durduran; Timothy C Zhu; Ken Kang-Hsin Wang
Journal:  Photochem Photobiol Sci       Date:  2009-10-15       Impact factor: 3.982

Review 10.  Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging.

Authors:  Daniel J Rohrbach; Daniel Muffoletto; Jonathan Huihui; Rolf Saager; Kenneth Keymel; Anne Paquette; Janet Morgan; Nathalie Zeitouni; Ulas Sunar
Journal:  Acad Radiol       Date:  2014-02       Impact factor: 3.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.